Open AccessEffects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2
Author(s) -
George L. Bakris,
Megumi Oshima,
Kenneth W. Mahaffey,
Rajiv Agarwal,
Christopher P. Can,
George Capuano,
David M. Charytan,
Dick de Zeeuw,
Robert Edwards,
Tom Greene,
Hiddo J.L. Heerspink,
Adeera Levin,
Bruce Neal,
Richard Oh,
Carol A. Pollock,
Norman Rosenthal,
David C. Wheeler,
Hong Zhang,
Bernard Zinman,
Meg Jardine,
Vlado Perkovic
Publication year - 2020
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.10140620
Subject(s) - canagliflozin , medicine , renal function , hazard ratio , confidence interval , population , empagliflozin , urology , diabetes mellitus , creatinine , placebo , albuminuria , type 2 diabetes , gastroenterology , endocrinology , alternative medicine , environmental health , pathology
Background and objectives The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduced the risk of kidney failure and cardiovascular events in participants with type 2 diabetes mellitus and CKD. Little is known about the use of SGLT2 inhibitors in patients with eGFR 300–5000 mg/g, and an eGFR of 30 to 0.20). The estimate for kidney failure in participants with eGFR 0.12). Conclusions This post hoc analysis suggests canagliflozin slowed progression of kidney disease, without increasing AKI, even in participants with eGFR <30 ml/min per 1.73 m 2 .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom